Article
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
Hematology/oncology clinics of North America - 1 Aug 2017
Ghiaur Gabriel, Levis Mark
Abstract excerpt
The presence of FLT3 mutations in acute myeloid leukemia (AML) carries a particularly poor prognosis, making the development of FLT3 inhibitors an imperative goal. The last decade has seen an abundance of clinical trials using these drugs alone or in combination with chemotherapy. This culminated with the recent approval by the US Food and Drug Administration of Midostaurin for the treatment of FLT3-mutated AML....
Topics
- Antineoplastic Agents
- Bone Marrow
- Cell Survival
- Cellular Microenvironment
- Drug Resistance, Neoplasm
- Gene Duplication
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- Signal Transduction